Creating new types of peptides to target difficult proteins
Genetic code expansion for the construction of beyond rule-of-5 compliant macrocyclic peptide libraries
This study is exploring new types of peptides that can target tough protein interactions that regular medicines can't, with the hope of finding better treatment options for patients with various diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10836474 on NIH RePORTER |
What this research studies
This research focuses on developing innovative macrocyclic peptides that can interact with challenging protein-protein interactions that traditional drugs cannot target. By utilizing advanced techniques like mRNA display, the researchers aim to create vast libraries of peptide variants that go beyond the typical size limitations of existing drugs. This approach seeks to enhance the diversity of peptide libraries, allowing for the discovery of more effective inhibitors for various diseases. Patients may benefit from new treatment options that can effectively target previously 'undruggable' proteins.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with diseases caused by protein-protein interactions that are difficult to target with existing medications.
Not a fit: Patients with conditions that do not involve protein-protein interactions or those who are already effectively treated with existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies for diseases that currently have limited treatment options.
How similar studies have performed: Other research has shown promise in using peptide libraries for drug discovery, indicating that this approach could yield significant advancements.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Hartman, Matthew C — Virginia Commonwealth University
- Study coordinator: Hartman, Matthew C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.